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Background: Central venous catheter (CVC) and hemodialysis (HD) catheter usage are associated with
complications that occur during catheter insertion, dwell period, and removal. This study aims to identify and
describe the incidence rates of catheter-related complications in a large patient population in a United States-based
health care claims database after CVC or HD catheter placement.
Methods: Patients in the i3 InVision DataMart® health care claims database with at least 1 CVC or HD catheter
insertion claim were categorized into CVC or HD cohorts using diagnostic and procedural codes from the US Renal
Data System, American College of Surgeons, and American Medical Association’s Physician Performance Measures.
Catheter-related complications were identified using published diagnostic and procedural codes. Incidence rates
(IRs)/1000 catheter-days were calculated for complications including catheter-related bloodstream infections
(CRBSIs), thrombosis, embolism, intracranial hemorrhage (ICH), major bleeding (MB), and mechanical catheter–
related complications (MCRCs).
Results: Thirty percent of the CVC cohort and 54% of the HD cohort had catheter placements lasting <90 days.
Catheter-related complications occurred most often during the first 90 days of catheter placement. IRs were highest for
CRBSIs in both cohorts (4.0 [95% CI, 3.7-4.3] and 5.1 [95% CI, 4.7-5.6], respectively). Other IRs in CVC and HD cohorts,
respectively, were thrombosis, 1.3 and 0.8; MCRCs, 0.6 and 0.7; embolism, 0.4 and 0.5; MB, 0.1 and 0.3; and ICH, 0.1 in
both cohorts. Patients with cancer at baseline had significantly higher IRs for CRBSIs and thrombosis than non-cancer
patients. CVC or HD catheter–related complications were most frequently seen in patients 16 years or younger.
Conclusions: The risk of catheter-related complications is highest during the first 90 days of catheter placement in
patients with CVCs and HD catheters and in younger patients (≤16 years of age) with HD catheters. Data provided in
this study can be applied toward improving patient care.
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thrombosisBackground
Central venous catheters (CVCs) refer to prolonged vascu-
lar access devices indicated for the administration of intra-
venous medication treatments, fluids, or total parenteral
nutrition, repeated blood sampling, and for hemodialysis
(HD) [1,2]. Annual CVC exposure in hospital intensive
care units has been estimated to total 15 million days [3]
in the United States. Use of CVCs for HD (hereafter re-
ferred to as HD catheters) has increased in recent years,* Correspondence: napalkov.pavel@gene.com
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reproduction in any medium, provided the orcomprising approximately 25% of prevalent HD patients
in the United States [4]; this is despite the recommenda-
tion by the National Kidney Foundation that tunneled,
cuffed catheters for HD access be limited to <10% of
prevalent dialysis patients due to the greater risk of mor-
bidity and mortality [5]. Long-term dialysis using tun-
neled, cuffed catheters increases a patient’s risk of death
2- to 3-fold and serious infection 5- to 10-fold compared
with dialysis using arteriovenous fistulas [1]. Additionally,
compared with the general population, dialysis patients
have a 100-fold greater risk of sepsis-related death, withal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with catheters [6].
CVC- and HD-catheter usage are associated with com-
plications that occur during catheter insertion, throughout
the catheter dwell period, and at the time of removal.
Identification and prevention of catheter-related complica-
tions is critical to improving patient care [7,8]. Common
complications include catheter misplacement or breakage,
catheter occlusion due to local or systemic infection, and
thrombosis [7-11].
Reported incidence rates (IRs) of catheter-related com-
plications vary widely depending on the terminology and
definition of complications, patient population, units of
measurement, duration of catheterization and follow-up,
catheter location, placement and care procedures, and
diagnostic methods [9]. Patients undergoing HD may
have different complication rates than non-HD patients.
The US Renal Data System provides guidelines for the
coding of HD catheter procedures [10-12]. Therefore,
investigating complication rates in patients with and
without HD catheter procedures is possible and import-
ant for understanding IRs in different patient groups.
The most common type of complication is catheter-
related bloodstream infection (CRBSI), with an incidence
rate of 0.46 to 30 per 1000 catheter-days, or in 4.3% to
26% of placed catheters [13-19]. In addition, many cen-
tral venous access devices (CVADs) develop a fibrin
layer (usually within 24 hours after insertion) which
may cause CVAD dysfunction over time [20]. Catheter-
related thrombosis has been reported in 0.6% to 33%
of catheters, or 0.06 to 21 episodes/1000 catheter-days
[9,14,21-23]. In patients with hematologic malignancy,
the incidence of symptomatic CVC-related thrombosis
varies between 1.2% and 13% [9]. Other less common
complications that may be related to the treatment of
occluded catheters include intracranial hemorrhage
(ICH), major bleeding (MB), and embolism [21,24-26].
The objective of this study was to obtain unadjusted
IRs of first complications after catheter insertion in a
real-world setting. Previous studies have reported com-
plication rates in patients with catheters; however, to our
knowledge no studies have described incident complica-
tions of CVCs, including HD catheters, in both adults
and children at different time periods following inser-
tion. The current study uses a consistent methodologic
approach to identify and describe the IRs of select first
complication events after catheter insertion in a large,
geographically diverse US patient cohort. This is import-
ant for improving patient care.
Methods
Study design and data source
A retrospective cohort analysis of the i3 InVision
DataMartW administrative claims database was conductedto determine the IRs of select complications in patients
with either CVC or HD catheter replacement or removal.
The i3 InVision database is a proprietary sample of indi-
viduals receiving health insurance benefits from a large
health plan, comprising discounted fee-for-service inde-
pendent practice association plans throughout the United
States. The database includes medical, pharmacy, and lim-
ited laboratory claims for more than 39 million patients.
Of these, over 24 million have been continuously enrolled
for 12 or more months during the study period,
representing approximately 8.2% of the 2000–2007 gen-
eral US population [27].
Patients in the database between May 2000 and January
2007, with at least 1 claim for CVC or HD catheter inser-
tion and a record of having a catheter removal or replace-
ment procedure, were included in the initial data cut.
Among these patients, those who were continuously en-
rolled in the health plan for 180 days prior to the first
CVC or HD catheter placement and who had no compli-
cation events during this 180-day period were included in
the study. Requiring patients to be free of defined com-
plications prior to catheter placement and to have both
catheter placement and removal or replacement claims
allowed us to more accurately attribute study outcome
events to catheter procedures in order to ensure a mean-
ingful interpretation of catheter-related complications
from claims data.
Patients were followed from the date of their first quali-
fying claim for insertion of either type of device (index
date) until onset date of each distinct CVC or HD cath-
eter–related complication event or other censoring date,
such as the date of catheter removal or replacement,
health plan termination, or end of study, whichever oc-
curred first. In patients with multiple catheter insertion
and removal or replacement claims, only the patient’s first
qualifying placement claim was counted as the index date
for IR calculation of study outcomes. In patients who were
censored at catheter removal or replacement, only the pa-
tient’s first such claim was counted if multiple removal or
replacement claims were on record.
Catheter placements, as well as removals and replace-
ments were identified using combinations of codes from
the International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) [28], Current Proced-
ural Terminology (CPT), and Healthcare Common Pro-
cedure Coding System (HCPCS) based on categories and
groupings proposed by the US Renal Data System [10-12],
the American College of Surgeons [29], and the Physician
Consortium for Performance Improvement [30]. Patients
were categorized into 2 mutually exclusive cohorts (CVC
or HD catheter, with HD catheter placement taking prece-
dence given the greater specificity of claim codes consistent
with HD catheter insertion). Patients with an HD catheter
placement claim who also had at least 1 claim for
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period prior to or following their HD catheter insertion
claim were excluded. Patients in the CVC cohort were
further classified as those with or without cancer at
baseline (i.e., prior to CVC placement) using ICD-9-CM
diagnosis codes for malignant neoplasms. Codes and
definitions used to identify and assign patients into co-
horts are listed in Additional file 1.
Outcome events
Outcome events included first (incident) complications
after catheter insertion that occurred during at least 1
overnight hospitalization or a hospital emergency room
visit which did or did not result in hospitalization and
were each identified using ICD-9-CM diagnostic or
CPT procedure codes (Additional file 1) consistent with
catheter-related blood stream infections, thrombosis, em-
bolism, intracranial hemorrhage, major bleeding events,
and mechanical catheter–related complications (MCRCs).
The first or only occurrence of any of the above complica-
tions was also defined as an outcome and used for the IR
calculation of the “Any complication” category. In patients
with only 1 or multiple complications of the same type,
the first or only complication occurrence was included in
the IR calculation for specific types of events. In patients
with multiple complication events of different types, the
first occurrence of each distinct complication was used for
the IR calculation of specific event types.
Statistical analyses
Patient characteristics, including gender and age (with
categories of <2, 2–16, 17–64, and ≥65 years) and dur-
ation of catheter placement (with time periods of 1
to <90, 90 to <180, 180 to <365, and ≥365 days) were
reported for the HD and CVC cohorts as well as for the
CVC patients by cancer-at-baseline status; the HD co-
hort did not include any patients younger than 2 years
of age. IRs were calculated as the total number of com-
plication events that occurred within the defined cath-
eter placement period divided by the sum of the
catheter-days at risk during the period of catheter place-
ment and were expressed per 1000 catheter-days. The
95% confidence interval (CI) of the IR was calculated
based on a normal approximation, under the assumption
that the number of events follows a Poisson distribution.
The 95% CI was expressed as: Exp{ln(incidence rate) ±
1.96 sqrt(1/total number of events)}. Catheter-days at
risk were defined as the number of days between
catheter insertion and event onset date (i.e., first out-
come event) or the earliest date of catheter removal or
replacement, health plan termination, or end of study.
Catheter-days differed for each complication event and
within each event catheter placement duration period
because patients were censored at variable event dates.Fisher’s exact test was used to determine statistical sig-
nificance of differences in IRs between CVC patients
with or without cancer at baseline.
A sensitivity analysis was also conducted to determine
if eliminating the requirement for having a catheter re-
moval or replacement claim had an effect on complica-
tion rates. We calculated the IRs of complications in the
first 90 days of catheter placement by using less strin-
gent censoring criteria and eliminating the requirement
to have a catheter removal or replacement claim.
Results
Patient disposition and characterization
Patient assignment to the CVC and HD catheter cohorts
is represented in Figure 1. Included in the study were
16,721 and 5,984 patients who underwent removal or re-
placement of a CVC or HD catheter, respectively. Patient
characteristics, including duration of catheter placement
are summarized in Table 1.
Incidence of catheter-related complications
The IRs of any catheter-related complications by dur-
ation of catheter placement are depicted in Figure 2, cat-
egorized by patient cohort (HD catheter or CVC), as
well as cancer-at-baseline status (CVC cohort only).
CVC patients with cancer at baseline had statistically
significantly higher rates of any complication compared
with CVC patients without cancer during the first
90 days of catheter placement (P = .0001). For all cath-
eter placement periods after 90 days, patients with
cancer at baseline had statistically significantly lower
complication rates than patients with no reported cancer
in the same catheter placement period (Figure 2).
Table 2 presents the IRs of specific and any CVC and
HD catheter–related complications among patients with
catheter placement lasting less than 90 days. For specific
complications, CRBSIs had the highest IR, 4.0 for CVCs
(95% CI, 3.7-4.3) and 5.1 for HD catheters (95% CI, 4.7-
5.6), followed by thrombosis, 1.3 for CVCs (95% CI, 1.1-
1.4) and 0.8 for HD catheters (95% CI, 0.7-1.0). Other
IRs for CVCs and HD catheters were lower, ranging
from 0.09 (MB in CVCs) to 0.68 (MCRCs in HD cathe-
ters). The IRs for ICH were identical (0.10) in both co-
horts. The incidences of CRBSIs, thromboses, and any
complication were significantly higher in patients with
cancer at baseline than in those with no reported cancer
(P < .05 for each type of complication).
The IRs of any catheter-related complications occur-
ring in the first 90 days of catheter placement are shown
by patient cohort, baseline cancer status, and patient age
in Figure 3. Among CVC patients with baseline cancer,
younger patients (in combined age groups <2 and 2–
16 years, data not shown) had statistically significantly
higher rates of any complication compared with older
Patients with HD catheter placement 
claim and renal dialysis/failure within 
30 days before or after any HD 
catheter insertion claim*
(n = 30,015)
Exclude: Patients with claims for 
chemotherapy/parenteral nutrition 
within 30 days before or after any 
HD catheter insertion claim
(n = 811)
Patients with no 
chemotherapy/parenteral nutrition 
claims within 30 days before or after 
any HD catheter insertion claim
(n = 29,204)
Patients with cancer claims within 
180 days prior to CVC placement
(n = 50,952)
Patients with no cancer claims within 
180 days prior to CVC placement
(n = 93,036)
HD catheter cohort: Patients with 
catheter removal or replacement 
procedures after insertion
(n = 5,984)
CVC cancer cohort: Patients with 
catheter removal or replacement 
procedures after insertion
(n = 12,531)
CVC no cancer cohort: Patients 
with catheter removal or replacement 
procedures after insertion 
(n = 4,190)
CVC cohort: Patients with CVC 
placement claim and no specific 
codes for HD catheter placement 
and renal dialysis/failure within 
30 days
(n = 143,988)
Patients with 180 days of continuous 
enrollment prior to first CVC or HD 
catheter placement claim
(n = 174,003)
Figure 1 Patient assignment into CVC and HD cohorts. CPT, Current Procedural Terminology; CVC, central venous catheter; HD, hemodialysis.
*With the exception of CPT code 36800 “Insertion of cannula for hemodialysis, other purpose (separate procedure); vein to vein” that does not
require an accompanying renal dialysis or renal failure claim.
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between younger and older age groups in CVC patients
without cancer. HD patients in age group 2–16 years
had statistically significantly higher rates of complica-
tions versus older age groups (P = .0019). Temporal
trends for the most frequent complications (i.e., CRBSI
and thrombosis) were examined in both CVC and HD
catheter cohorts over the 2001–2006 study period and
there was no consistent evidence suggesting substantive
changes in the incidence of either CRBSIs or catheter-
related thrombosis during this period (Figure 4).
In the sensitivity analysis, during the first 90 days of
catheter placement, the IRs for the most common com-
plications decreased while rates for embolism, ICH, and
MB increased slightly. The decrease in IR for CRBSI
(from 4.0 to 1.6) was more substantial than for throm-
bosis (from 1.3 to 0.8) among patients in the CVC co-
hort (Additional file 2).
Discussion
This study analyzed the incidence of catheter-related
complications occurring in a real-world setting using a
single, large population sample and consistent methodsto identify and calculate unadjusted IRs for these different
complications. The results demonstrate that the highest
rates of first complications after CVC and HD ca-
theterization occur during the first 90 days of catheter
placement. Rates of complications are also higher in can-
cer patients with CVC placements than in non-cancer
patients during the first 90 days of catheter insertion.
Complication rates in children with HD catheters and
with CVCs with cancer at baseline are higher than in the
respective catheter cohorts for adults and elderly patients.
Earlier reports of IRs of catheter-related complications
were characterized by great variability due to inconsist-
encies in terminology, study design and methodology,
small sample sizes, and heterogeneity of patient popula-
tions. For example, some studies did not differentiate
embolism from thrombosis [31], and others did not
clearly define the specific types of “catheter malfunction”
being studied [14,32,33]. This study utilized diagnostic
and procedural codes from a large administrative claims
database to extract data describing the most common
complications following CVC or HD catheter insertion.
The finding that catheter-related complications were
considerably more common during the first 90 days
Table 1 Characteristics of patients with central venous and hemodialysis catheters*
Characteristic HD catheters CVC all CVC CVC
n = 5,984 n = 16,721 cancer no cancer
n = 12,531 n = 4,190
Age, years, n (%)
<2 0 (0) 188 (1.2) 66 (0.5) 122 (2.9)
2–16 115 (1.9) 933 (5.6) 449 (3.6) 484 (11.6)
17–64 4,052 (67.7) 13,655 (81.7) 10,665 (85.1) 2,990 (71.4)
≥65 1,817 (30.4) 1,945 (11.6) 1,351 (10.8) 594 (14.2)
Mean (SD) 56.1 (16.1) 48.1 (16.4) 49.5 (14.4) 43.9 (20.8)
Median (IQR) 57 (46, 68) 50 (41, 58) 51 (43, 58) 47 (32, 58)
Sex, n (%)
Female 2,646 (44.2) 11,281 (67.5) 9,068 (72.4) 2,213 (52.9)
Male 3,338 (55.8) 5,440 (32.5) 3,463 (27.6) 1,977 (47.2)
Duration of catheter placement,† days, n (%)
1 to <90 3,213 (53.7) 5,060 (30.3) 2,479 (19.8) 2,581 (61.6)
90 to <180 1,344 (22.5) 4,029 (24.1) 3,498 (27.9) 531 (12.7)
180 to <365 932 (15.6) 4,811 (28.8) 4,286 (34.2) 525 (12.5)
≥365 495 (8.3) 2,821 (16.9) 2,268 (18.1) 553 (13.2)
Mean (SD) 145 (208.5) 219.5 (227.4) 238.8 (214.1) 161.8 (254.6)
Median (IQR) 78 (29, 173) 164 (66, 283) 186 (110, –302) 55 (22, 184)
*Analysis only counted each patient’s first qualifying catheter insertion; †Duration of catheter placement = time from catheter insertion to first qualifying outcome
event, catheter replacement or removal, health plan termination, or study end.
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Figure 2 Incidence of any catheter-related complication by baseline cancer status and duration of catheter placement. Vertical bars
indicate 95% confidence intervals (CIs). CVC, central venous catheter; HD, hemodialysis.
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Table 2 Incidence rates of complications among patients with catheter placement* < 90 days
Type of
complication
Number of complications per 1000 catheter-days (95% CI)
HD catheters CVC all CVC cancer CVC no cancer
n = 3213 n = 5060 n = 2479 n = 2581
CRBSI 5.10 4.01 4.33† 3.62†
(4.69-5.55) (3.72-4.32) (3.92-4.78) (3.22-4.07)
Thrombosis 0.80 1.26 1.71† 0.76†
(0.65-0.98) (1.11-1.44) (1.46-2.00) (0.59-0.97)
MCRC 0.68 0.59 0.65 0.53
(0.55 -0.85) (0.49-0.72) (0.50-0.83) (0.40-0.72)
Embolism 0.49 0.39 0.38 0.40
(0.38-0.64) (0.31-0.49) (0.27-0.52) (0.28-0.56)
ICH 0.10 0.10 0.04† 0.17†
(0.06-0.18) (0.06-0.16) (0.02-0.11) (0.10-0.29)
MB 0.27 0.09 0.05 0.14
(0.19-0.39) (0.06-0.15) (0.02-0.12) (0.08-0.25)
Any‡ 6.98 6.00 6.67† 5.20†
(6.49-7.52) (5.64-6.38) (6.15-7.23) (4.71-5.74)
*Analysis only counted each patient’s first qualifying catheter insertion; †P < 0.05, Fisher’s exact test; ‡Defined as the initial occurrence of the first- or
only-occurring complication.
CI, confidence interval; CRBSI, catheter-related bloodstream infection; CVC, central venous catheter; HD, hemodialysis; ICH, intracranial hemorrhage; MB, major
bleeding; MCRC, mechanical catheter–related complication.
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some catheter-related complications eventually lead to
catheter removal (the censoring event in the present
study). Recurrent catheter insertions and complications
occurring after repeated catheter placements were not
evaluated.
In this study, the most frequent complications associated
with catheter placement were CRBSIs and catheter-related




































Figure 3 Incidence of any catheter-related complication during the fi
cohort, patient age, and baseline cancer status. There were no children <2
intervals (CIs). CVC, central venous catheter; HD, hemodialysis.low overall (4.4% of catheters or 1.3/1000 catheter-days). In
previous reports, the incidence of CVC-related thrombosis
varied widely (0.6%-33% of catheters) because of dif-
ferences in catheter type, study design and population,
and sensitivity of the examination procedures [9]. There
is growing evidence that catheter-related infection and
thrombosis are closely related because both involve fibrin
sheath formation, and the risk of clinically apparent throm-
bosis is markedly increased after an infection episode [9].ted complication 
eline cancer
Any CVC-related complication 
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Figure 4 Yearly incidence of CRBSI and thrombosis in patients with CVCs (A) or HD catheters (B). Data for 2001 to 2006 are shown.
Vertical bars indicate 95% confidence intervals (CIs). CRBSI, catheter-related bloodstream infection; CVC, central venous catheter; HD, hemodialysis.
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having the highest IRs in both the CVC and HD catheter
cohorts of our study.
A sensitivity analysis was also conducted to determine if
eliminating the requirement for having a catheter removal
or replacement claim had an effect on complication rates.
Comparison of findings from the first 90 days of catheter
placement (i.e., higher CRBSI IR with removal/replacement
requirement) demonstrates that some complications, such
as CRBSI, are more likely to result in catheter removal.
While CRBSI typically presents with visible symptoms, up
to two-thirds of patients with catheter-related thrombosis
are asymptomatic [9,34,35]. In most instances, catheters
causing CRBSI must be removed to resolve the problem[34]. In contrast, patients identified as having thrombosis
can be treated with thrombolytic therapy to resolve the
problem [35]. While patient age is considered a risk factor
for CRBSI (CRBSI is more common in children than in
adults [34]), the age distributions were similar in the main
and sensitivity analyses. In the sensitivity analyses, IRs for
relatively rare complications (e.g., embolism and ICH)
slightly increased. These findings could be related to de-
layed effects of treatment of occluded catheters rather than
catheter placement. Further studies are needed to investi-
gate these findings.
Consistent with earlier reports, our study showed a
higher frequency of catheter-related complications in pa-
tients with cancer than in non-cancer patients during
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the use of immunosuppressive cancer therapies. The risk
of infection is known to be particularly high in neutro-
penic patients and in patients undergoing chemotherapy
prior to stem cell transplantation [36]. More than one in-
sertion attempt (OR, 5.5), ovarian cancer (OR, 4.8), and
previous CVC insertion (OR, 3.8) are also significant base-
line risk factors for catheter-related thrombosis in cancer
patients [37]. In particular, the risk of developing CVC-
related thrombosis is significantly higher in patients with
cancer who also carry the factor V Leiden mutation
(reported relative risk from 2.6 to 7.7) [38,39], or have
hyperhomocysteinemia (reported ORs from 3.8 (95% CI,
1.3-11.3) [40] to as high as 33.9 (95% CI, 1.53-751.33)
[41]), compared with patients without these conditions.
Further analyses based on these and other risk factors are
warranted, and may yield new insights into the manage-
ment of cancer patients with indwelling catheters.
Although the incidence of catheter-related complica-
tions was significantly higher in CVC patients with cancer
at baseline compared with non-cancer patients during the
first 90 days of catheter placement, non-cancer patients
(i.e., patients in HD catheter or CVC non-cancer groups)
had greater incidences of any type of complication in cath-
eter placement periods lasting 90 days or longer. One pos-
sible explanation for this finding is that over time, cancer
patients (presumably the more severely ill group and in-
herently different from non-cancer patients) had poorer
survival than the non-cancer patients, resulting in their re-
duced contribution to lengthier catheter time periods. It
is also plausible that the severity of complications in
these cancer patients necessitated earlier catheter removal
(within the first 90 days), whereas in the non-cancer
group, complications occurred and catheters were re-
moved later. Because of limitations of the claims database,
comorbid conditions and other factors possibly contribut-
ing to outcome events were not assessed in any of the
groups.
This analysis was based on automated medical and
prescription claims. While claims data are extremely
valuable for the efficient and effective examination of
health care outcomes, all claims databases have certain
inherent limitations because the claims are collected pri-
marily for the purpose of reimbursement for health ser-
vices and not for research. The presence of a diagnosis
code on a medical claim does not always indicate posi-
tive presence of disease because claims data are subject
to errors in coding, inaccurate disease classification, or
may include a ‘rule out’ diagnostic workup rather than
actual disease. To increase the specificity in outcome
identification, we required 1 overnight hospitalization or
a hospital emergency room visit and used validated diag-
nostic and procedural codes identifying these conditions
from published literature [10-12,29,30]. Although weattempted to utilize precise codes to identify catheter
type, cancer status, and outcome events, coding errors
may have misclassified some patients. An additional po-
tential confounder is the inability to distinguish from
claims data whether catheterization was the cause of the
defined outcome event or the indication for the outcome
event. However, we imposed patient selection require-
ments (i.e., 180 days of outcome-free enrollment prior to
index and record of catheter insertion and removal or
replacement claims) in order to correctly ascertain the
temporal relationship between the exposure and out-
come event.
There is also a potential for misclassification regarding
patient ascertainment to either HD catheter or CVC
groups. However, to more accurately categorize patients in
these 2 groups, we used coding recommended by the US
Renal Data System and further required patients in the
HD cohort not to have claims for chemotherapy or paren-
teral nutrition within 30 days of HD catheterization. Pa-
tients without HD procedure codes were allocated into
CVC cohort.
Another limitation of our study was that patients in
the database we utilized were commercially insured and
might not be completely generalizable to the general US
population. There is limited ability in claims data to
determine whether demographic characteristics of the
study population are similar to the general population.
However, the age distribution of the study population
was similar to that in the general US population during
the same time period.
Previous studies showed that site of catheter insertion
can influence the incidence of certain catheter-related
adverse events such as infectious and thrombotic com-
plications [22,42,43]. Limitations inherent to claims data
did not allow us to determine the type of catheter device
used (tunneled vs. non-tunneled devices), the site of the
catheter insertion, or whether the catheter that was re-
moved during the 90-day period was the same catheter
that was placed. The extent to which “good” catheter
placement and care recommendations are practiced can
also influence complication rates; however, the claims
data source did not permit us to determine whether
techniques including sterilization methods (e.g., ethanol
locks) were utilized at the clinical level. It was also not
possible to determine whether lag time between the ac-
tual catheter removal or replacement and claims pro-
cessing dates may have biased our results.
Future analyses examining the correlation of claims
for infection and thrombosis may provide more insight
into the possible simultaneous occurrence of these com-
plications. While patients who require long-term vascu-
lar access are generally very sick, patients who require
catheters for HD may differ in important ways from
those who require CVADs for medical conditions other
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could provide further guidance for improving the care of
patients who are severely or chronically ill.
Conclusion
This study provides a new body of data on the risk of
catheter-related complications derived from a large pa-
tient population. The risk of catheter-related complica-
tions is highest during the first 90 days of catheter
placement in patients with CVC and HD catheters and
in younger patients (≤16 years of age) with HD cathe-
ters. In younger patients (<2 years of age and 2–16 years
of age, combined) with CVCs the risk of complications
is higher than in patients over 16 years of age only in pa-
tients with cancer at baseline. This information provides
valuable additional context for the development of strat-
egies for the management of dysfunctional CVC and HD
catheters and for improved patient care.
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